Trial Profile

A retrospective study of effectiveness and safety of vedolizumab and ustekinumab in patients with Crohn's-disease

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 24 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ustekinumab (Primary) ; Ustekinumab (Primary) ; Vedolizumab (Primary)
Indications Crohn's disease
Focus Therapeutic Use

Most Recent Events

11 Oct 2022 Results presented at the 30th United European Gastroenterology Week
13 Oct 2020 Results (n=180) assessing vedolizumab clinical decision support tool as a predictive factor of response of vedolizumab and ustekinumab, in patients with Crohn's disease, presented at the 28th United European Gastroenterology Week.
09 Apr 2020 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com